Paula Guardia Martínez (Servicio de Cardiología, Hospital Costa del Sol, Marbella, Málaga), Alberto Luis Avilés Toscano (Servicio de Cardiología, Hospital de la Serranía de Ronda, Málaga), María Asunción Martínez Mayoral (Departamento de Estadística, Matemáticas e Informática, Universidad Miguel Hernández de Elche, Alicante)
Abstract:
Direct oral anticoagulant (DOAC) therapy has been shown to be safe and effective in patients with atrial fibrillation (AF). However, outcomes in AF patients with bioprosthetic valves are unclear, as this population has been underrepresented in clinical trials. The aim of this study was to assess the safety and efficacy of DOACs in this population based on the existing published literature.